ME-3241

Meiji Seika Pharma has initiated a Phase I clinical trial in Australia evaluating ME3241, an anti-PD-1 agonist monoclonal antibody intended for autoimmune and inflammatory diseases. The molecule emerged from FBRI collaborative research led by Tasuku Honjo, the Nobel laureate and Kyoto University professor emeritus whose foundational work on PD-1 underpins modern cancer immunotherapy. ME3241 inverts that logic: rather than blocking PD-1 to unleash immune attack on tumors, it stimulates the receptor to suppress pathological immune responses. The ME3241 clinical trial (NCT07422207) is a randomized, placebo-controlled, double-blind study in healthy adult participants, evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics following single and multiple intravenous doses. The AllSci trial listing confirms the study has not yet begun recruiting. No specific autoimmune indication has been disclosed for future efficacy studies; the company states broadly that ME3241 has potential as a therapeutic for inflammatory diseases including autoimmune conditions caused by excessive immune responses. Findings supporting the conditions required to induce immunosuppression via PD-1 agonist antibodies were published in Science Immunology in January 2023. Research context The rationale for PD-1 agonism in autoimmunity rests on the receptor’s physiological role as a negative regulator of T cell activation. Preclinical work has shown that cell-targeted PD-1 agonists mimicking PD-L1 can potently inhibit T cell responses (AllSci), and reviews of PD-1 signaling in health and disease reinforce its centrality to immune homeostasis (AllSci). Rosnilimab, a separate clinical-stage PD-1 agonist IgG1 antibody, has demonstrated that membrane-proximal binding can optimize agonist signaling (AllSci), providing additional translational validation. ME3241 is described as having enhanced PD-1 agonist activity, though the structural or engineering basis for this has not been disclosed. Current treatment for autoimmune diseases relies on corticosteroids, conventional immunosuppressants such as methotrexate, and targeted biologics including TNF inhibitors (adalimumab, AbbVie), IL-6 inhibitors (tocilizumab, Roche), JAK inhibitors (tofacitinib, Pfizer; upadacitinib, AbbVie), and B-cell depleting agents (rituximab, Roche). Recent approvals have expanded options: anifrolumab (AstraZeneca) for lupus, bimekizumab (UCB) across psoriatic indications, and FcRn blockers such as efgartigimod (Argenx) for antibody-mediated conditions (AllSci). Despite this, 30 to 40 percent of patients with conditions like rheumatoid arthritis or inflammatory bowel disease do not respond adequately to first-line biologics, secondary loss of response is common, and JAK inhibitors carry boxed warnings for cardiovascular and malignancy risks. Corticosteroid dependence remains pervasive. These therapies largely target downstream cytokines rather than restoring immune tolerance, a gap PD-1 agonism could theoretically address. The competitive field for PD-1 agonists in autoimmunity is thin. Based on available data, Seismic Therapeutic’s S-4321, a bifunctional PD-1 agonist with FcγRIIb selectivity targeting both T cells and B cells, entered Phase I around 2025. No other PD-1 agonist programs for autoimmune indications appear in active clinical development. ME3241 and S-4321 diverge in design: ME3241 is a monospecific antibody with enhanced agonist activity, while S-4321 employs a dual-mechanism approach. Both remain at the earliest clinical stage, and neither has generated human efficacy data. The absence of additional entrants underscores how nascent this mechanistic class remains, and how far it sits from the crowded cytokine-targeting landscape that dominates autoimmune drug development today. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website